JP2012510484A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510484A5
JP2012510484A5 JP2011538906A JP2011538906A JP2012510484A5 JP 2012510484 A5 JP2012510484 A5 JP 2012510484A5 JP 2011538906 A JP2011538906 A JP 2011538906A JP 2011538906 A JP2011538906 A JP 2011538906A JP 2012510484 A5 JP2012510484 A5 JP 2012510484A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
minutes
administration
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011538906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510484A (ja
JP5778037B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/008857 external-priority patent/WO2010063493A1/en
Publication of JP2012510484A publication Critical patent/JP2012510484A/ja
Publication of JP2012510484A5 publication Critical patent/JP2012510484A5/ja
Application granted granted Critical
Publication of JP5778037B2 publication Critical patent/JP5778037B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011538906A 2008-12-03 2009-12-03 ベンダムスチンの経口投与剤 Expired - Fee Related JP5778037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03
EP08075915.2 2008-12-03
PCT/EP2009/008857 WO2010063493A1 (en) 2008-12-03 2009-12-03 Oral dosage forms of bendamustine

Publications (3)

Publication Number Publication Date
JP2012510484A JP2012510484A (ja) 2012-05-10
JP2012510484A5 true JP2012510484A5 (https=) 2013-01-24
JP5778037B2 JP5778037B2 (ja) 2015-09-16

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011538906A Expired - Fee Related JP5778037B2 (ja) 2008-12-03 2009-12-03 ベンダムスチンの経口投与剤

Country Status (25)

Country Link
US (4) US20120003305A1 (https=)
EP (1) EP2367542B1 (https=)
JP (1) JP5778037B2 (https=)
KR (1) KR101688038B1 (https=)
CN (2) CN105363037B (https=)
AU (1) AU2009321745B2 (https=)
BR (1) BRPI0922806B8 (https=)
CA (1) CA2745525A1 (https=)
CO (1) CO6400183A2 (https=)
CY (1) CY1114977T1 (https=)
DK (1) DK2367542T3 (https=)
EA (1) EA020354B1 (https=)
ES (1) ES2451540T3 (https=)
HR (1) HRP20140204T1 (https=)
IL (1) IL213270A (https=)
MX (1) MX2011005643A (https=)
NZ (1) NZ592970A (https=)
PL (1) PL2367542T3 (https=)
PT (1) PT2367542E (https=)
RS (1) RS53201B (https=)
SI (1) SI2367542T1 (https=)
SM (1) SMT201400053B (https=)
UA (1) UA102120C2 (https=)
WO (1) WO2010063493A1 (https=)
ZA (1) ZA201103791B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
EP2760842B1 (en) * 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
ES2936387T3 (es) 2011-10-31 2023-03-16 Hoffmann La Roche Formulaciones de anticuerpos anti-il13
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
KR20150086308A (ko) * 2012-11-12 2015-07-27 이그니타, 인코포레이티드 벤다무스틴 유도체 및 그의 사용 방법
ES2670995T3 (es) 2013-03-12 2018-06-04 Cephalon, Inc. Formulaciones de nanopartículas y macropartículas
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
RU2020115024A (ru) 2017-10-05 2021-11-08 Тьюб Фармасьютикалз Гмбх Препараты бендамустина для перорального введения

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
MX2007005361A (es) * 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Similar Documents

Publication Publication Date Title
JP2012510484A5 (https=)
HRP20140204T1 (hr) Oralni oblici doziranja bendamustina
JP6938462B2 (ja) 治療用化合物の脳への一方向送達のためのインプラント組成物
TWI841481B (zh) 乳酸鈣組成物及使用方法
JP2020528880A5 (https=)
MY173881A (en) Oral dosage forms of bendamustine and therapeutic use thereof
JP2020505433A (ja) Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
TW200924756A (en) Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
CN109475524A (zh) 用于减少中性粒细胞减少症的组合物和方法
CN116785301A (zh) 含醋酸阿比特龙的药物组合物及其制备方法和应用
CA3080644A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
JP2018503610A5 (https=)
KR20210005714A (ko) 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
TW202425975A (zh) 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
JP6170946B2 (ja) ロミデプシン製剤及びその使用
WO2024102187A1 (en) Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain
US11304898B2 (en) Method of treating carcinoma
CN110831592A (zh) 医药
CN112535688A (zh) 药物组合
Rummel German experience with bendamustine treating Relapsed/Refractory indolent B-Cell and mantle cell lymphomas
KR20250145693A (ko) 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법
WO2026044119A1 (en) Treatment regimens for gedatolisib in hormonally-driven disorders
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合